Tc 99m nofetumomab merpentan

Drug Profile

Tc 99m nofetumomab merpentan

Alternative Names: F(ab)2 NRLU10 technetium (Tc 99m); OncoTrac; OncoTrac NSCLC; OncoTrac SCLC; Technetium Tc 99m-nofetumomab merpentan; VerLuma

Latest Information Update: 21 Jun 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Poniard Pharmaceuticals
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Organotechnetium compounds; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 21 Jun 2006 NeoRx Corporation is now called Poniard Pharmaceuticals Inc.
  • 22 May 1997 Launched for Small cell and Non-small cell lung cancer diagnosis in USA (IV)
  • 12 Feb 1997 Registered for Small cell and Non-small cell lung cancer diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top